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A B S T R A C T
Heart failure is a major public health problem throughout the world and it is likely that its prevalence
will continue to grow over the next several decades. Despite advances in the treatment of heart failure,
morbidity and mortality remain unacceptably high. Gene transfer therapy provides a novel strategy for
targeting abnormalities in cardiac cells that adversely affect cardiac function. New vectors for gene
delivery, mainly adeno-associated viruses (AAVs) that are preferentially taken up by cardiomyocytes,
can result in sustained transgene expression. The cardiac isoform of sarco(endo)plasmic reticulum
Ca2+ATPase (SERCA2a) plays a major role in regulating calcium levels in cardiomyocytes. Abnormal
calcium handling by the failing heart caused by a reduction in SERCA2a activity adversely affects both
systolic and diastolic function. The Calcium Upregulation by Percutaneous Administration of Gene
Therapy in Cardiac Disease (CUPID) study was a Phase 2a double-blind, randomized, placebo-controlled,
dose-ﬁnding study that was performed in patients with advanced heart failure due to systolic
dysfunction. Eligible patients received AAV/SERCA2a or placebo by direct antegrade infusion into the
coronary circulation. At the end of 12 months, patients receiving high-dose therapy (i.e. 1  1013 DNase
Resistant Particles) had evidence of favorable changes in several clinically relevant domains compared to
patients treated with placebo. There were no safety concerns at any dose of AAV/SERCA2a. Patients
treated with AAV/SERCA2a exhibited a striking reduction in cardiovascular events that persisted through
36 months of follow-up compared to patients who received placebo. Transgene expression was detected
in the myocardium of patients receiving AAV/SERCA2a gene therapy as long as 31 months after delivery.
A second Phase 2b study, CUPID 2, designed to conﬁrm this favorable effect on heart failure events, is
currently underway with the results expected to be presented later in 2015. Additional studies using
other vectors and targets are in planning or underway making gene transfer therapy one of the most
exciting new approaches under development for treating heart failure.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Heart failure is a global public health problem of considerable
magnitude with increases in prevalence noted in virtually every
region of the world [1–6]. The aging of the population is the most
important factor in this growth in the number of heart failure
patients. Improved survival with other cardiovascular diseases
for which heart failure is a late consequence, most notably
myocardial infarction (MI), has also contributed to this pandemic
as has the rapid rise in conditions such as obesity and diabetes
that predispose to heart failure [7–9]. Although many effective
therapies have been developed over the past 50 years, heart
failure morbidity and mortality remain unacceptably high and new
approaches for treating the increasing worldwide population of
heart failure patients are needed.
Gene transfer therapy
Gene transfer therapy refers to the introduction of recombinant
human genetic material to a patient in order to alter levels of a
protein that will either directly or indirectly (e.g. through paracrine
or systemic effects) affect organ function. Advances in cellular and
molecular biology over the past several decades have offered
insights into fundamental processes that lead to the development
of heart failure [10]. These include abnormalities in adrenergic
signaling, alterations in calcium handling, disturbances cardio-
myocyte relaxation, activation of pathways that result in cell death
and stimulation of pathways that lead to deposition of extracellu-
lar matrix within the myocardium. Changes in the levels or activity
of molecules that play critical roles in these pathways have been
identiﬁed and many of these abnormalities are potentially
treatable by gene transfer therapy [11]. In addition, monogenetic
disorders that are the cause of heart failure are also inviting targets
for gene transfer therapy.
The conditions required for successful gene transfer therapy are
dependent on the characteristics of the disease. Patients with
chronic heart failure suffer from a condition that is organ wide.
Even when the initiating cause of heart failure is a discrete event in
both time and distribution (e.g. MI), progressive changes in the
structure and function of spared myocardium due to increases in
regional wall stress and the inﬂuence of neurohormonal systems
that are activated in response to injury expands the area that is
involved to encompass the entire heart. Thus, gene transfer to treat
heart failure should target as much myocardium as possible.
Furthermore, since heart failure is a chronic, progressive disease,
therapy needs to be sustained over time in order for lasting
beneﬁts to be realized.
Gene delivery systems
Both non-viral and recombinant viral delivery systems for gene
transfer therapy have been developed. Whereas non-viral systems
are relatively easy to produce, allow incorporation of large size
cassettes of recombinant genetic material and have low biosafety
risk, they are used less often due to problems with transfection
efﬁciency and intracellular degradation of the genetic material.
Recombinant viral systems have become the preferred mode of
delivery based on high efﬁciency and the capacity for long-term
transgene expression. Some viral delivery systems are limited by
their reduced capacity to package genetic material. Previous
concerns about inconsistencies in bioavailability, purity, and
biosafety, however, have been largely addressed and viral vectors
have now been used to deliver genetic material to humans in
numerous clinical trials.
Among the viral vectors used for gene therapy, adenovirus,
adeno-associated virus (AAV) [12], and lentivirus vectors [13] havebeen most studied. AAVs have emerged as the preferred vector
for gene delivery based on the fact that they are minimally
immunogenic, have the capacity for long-term transgene expres-
sion, and have demonstrated an excellent biosafety record. In
addition, several strains of vectors are highly cardiotropic so that
problems associated with gene delivery to other organs through-
out the body can be minimized [14]. An important limitation of
using AAV vectors, however, is the presence of neutralizing
antibodies due to prior infection in a substantial percentage of
patients.
Gene transfer therapy for heart failure can be accomplished by
either direct introduction into the heart or presentation to the
myocardium via the circulation [15–17]. The former can be
accomplished by direct injection into the epicardial surface of the
heart. As this requires fairly wide exposure in order to reach all
segments of the myocardium, it is most useful when carried out
during open-heart surgery for another reason such as placement of
a ventricular assist device (VAD). Endocardial delivery is also
possible using catheter techniques that allow micropuncture and
delivery of the reagent at multiple sites in the ventricle at standard
depths. Delivery of genetic material through the circulation can be
accomplished by either direct antegrade injection through the
coronary arteries or retrograde introduction through the coronary
sinus into the venous system of the heart. When delivered in the
circulation, viral particles bind to surface receptors and are taken
up into cardiac cells by endocytosis. The viral particles are then
released into the cytoplasm where they are transported to the
nucleus where the viral capsid is disassembled to release the
genetic material. After double-stranded synthesis of the gene of
interest is complete, transcription and translation begin leading to
the production of the molecule of interest.
Targeting sarcoendoplasmic reticulum ATPase 2a to treat heart
failure
Dysregulation of calcium handling in cardiomyocytes plays an
important role in the contractile and relaxation abnormalities that
are seen in the failing heart [18,19]. Calcium that is released into
the cytosol from the sarcoplasmic reticulum during systole
activates actin and myosin coupling that results in myoﬁlament
shortening and the production of force. Re-uptake of calcium
during diastole governs the rate of relaxation. Control of calcium
ﬂux within cardiomyocytes is regulated by a variety of channels
and enzymes including the L-type calcium channel, the sodium/
calcium exchanger, the ryanodine receptor, and sarcoendoplasmic
reticulum ATPase (SERCA) 2a activity.
The role of SERCA2a is of particular importance [20]. This
enzyme is situated on the surface of the sarcoplasmic reticulum
(SR) where it regulates the re-uptake of calcium from the cytosol
into the SR during diastole. Not only does the reduction in cytosolic
calcium concentration determine the relaxation but it also allows
an adequate store of calcium to be available within the SR for
release during the ensuing systole. Downregulation of SERCA2a
has been demonstrated in both experimental animal models and
human patients with heart failure [21–27]. In homogenates of
human heart, even a modest decrement in SERCA2a protein
reduces enzyme activity to the extent that there is a substantial
increase in diastolic calcium concentration [28]. Abnormalities in
calcium ﬂux, relaxation, and contraction of cardiomyocytes from
the failing heart are associated with reduced SERCA2a activity and
they can be corrected by increasing SERCA2a activity by gene
transfer therapy. Both small and large animal models of heart
failure have been shown to respond favorably to treatment with
gene transfer therapy using a viral vector to deliver the SERCA2a
gene to the heart [29–33].
Fig. 1. Structure of the adeno-associated virus (AAV)1/sarco(endo)plasmic reticulum Ca2+ATPase (SERCA2a) vector used in the Calcium Upregulation by Percutaneous
Administration of Gene Therapy in Cardiac Disease (CUPID) studies. The AAV1/SERCA2a vector only incorporates inverted terminal repeats (ITRs) from AAV2 serotype,
resulting in <300 nucleotides of the wild-type AAV sequences in the vector genome. The single-stranded DNA is encapsulated in the AAV serotype 1 icosahedral capsid. The
SERCA2a expression cassette contains the following components: the cytomegalovirus immediate early enhancer/promoter (CMVie) driving transcription of sequences
including a hybrid intron from the commercial plasmid pCI, the huSERCA2a cDNA, and a bovine growth hormone polyadenylation signal (BGHpA).
Reproduced with permission from Greenberg et al. [38].
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The CUPID study used a modiﬁed Type 1 adenovirus, depicted in
Fig. 1, to deliver the human cDNA for SERCA2a to the hearts of
patients with advanced heart failure [34–36]. Entry criteria for the
study included the presence of advanced New York Heart
Association functional class III or IV symptoms of heart failure
due to either ischemic or non-ischemic disease and an ejection
fraction (EF) 0.35. Patients were required to be clinically stable on
optimal medical therapy for at least 30 days prior to entry, to have
impaired exercise capacity, and to have neutralizing antibody
titers of <1:2.
Qualifying patients were randomized in a double-blinded
fashion to receive either low, mid or high dose of AAV1/SERCA2a
or placebo by direct antegrade intracoronary injection over a 10-
min period. Patients were pre-treated with low-dose intravenous
nitroglycerin whenever possible based on preliminary data
suggesting that this strategy enhanced uptake into cardiomyocytes
[37]. Patients were then actively followed over a 12-month period
to determine the safety and efﬁcacy of the treatment regimens
and then for an additional 24 months to assess safety. The study
used a novel predeﬁned primary endpoint for efﬁcacy that was
based on concordant changes across multiple efﬁcacy domains.
The domains that were used, variables assessed, and criteria for
what was considered a meaningful change in individual patients
are outlined in Table 1.Table 1
Domains and variables used to assess the effects of AAV1/SERCA2a treatment in
CUPID.
Efﬁcacy domain Meaningful change
Symptomatic




Peak VO2 1.5 mL/kg/min
Biomarker
NT-proBNP 35% or 300 pg/mLa
Remodeling
Ejection fraction 3 or 5% absoluteb
End-systolic volume 20 mL or 10%a
Reproduced with permission from Jessup et al. [35].
AAV, adeno-associated virus; NYHA, New York Heart Association; SERCA2a,
sarco-endoplasmic reticulum Ca2+ATPase; MLWHFQ, Minnesota Living With
Heart Failure Questionnaire; 6MWT, 6-minute walk test; VO2, maximal oxygen
consumption; mL/kg/min, milliliters/kilogram/minute; NT-proBNP, N-terminal
of the prohormone brain natriuretic peptide; pg/mL, picograms/milliliter; mL,
milliliter.
a Whichever is greater.
b 3% for group, 5% for individual.The baseline characteristics of the CUPID population are
outlined in Table 2. Over the course of the study, there was no
evidence of an increase in any treatment emergent adverse event
in any of the groups that received gene transfer therapy nor were
there signiﬁcant differences between study groups in vital signs,
blood chemistries, hematologic variables, electrocardiographic
parameters, or arrhythmia burden. In contrast to patients in the
placebo group who showed evidence of worsening in measures of
heart failure severity across the domains, patients in the high-dose
(1  1013 DRP) group demonstrated improvement or stabilization
in all variables measured. These results are summarized in
Fig. 2. Thus, for the high-dose group, the CUPID study met its
pre-speciﬁed efﬁcacy endpoint. Simulation of the potential out-
comes of the CUPID study based on permutation test indicated a
high level of conﬁdence (>1:1000) that the results had not come
about as a play of chance.
Clinical events were also followed in the CUPID patients and
are depicted at the 1- and 3-year time points in Fig. 3. There was a
striking reduction in cardiovascular events in the high-dose
compared to the placebo cohort at the end of 12 months. Even
after 36 months, the differences in event rate between the high-
dose and placebo patients remained apparent. Hospitalization
for heart failure was common, as would be expected in the
advanced heart failure population included in CUPID. TreatmentTable 2
Description of patients enrolled in CUPID.
Characteristic All subjects
N = 39
Age, years, mean (SD) 60.5 (11.5)
Sex, n 34 male
Race, n 34 White
HF etiology, n (%)
Ischemic cardiomyopathy 19 (48.7)
Idiopathic cardiomyopathy 14 (35.9)
Hypertensive cardiomyopathy 4 (10.3)
Other 3 (7.7)
6MWT, m, mean (SD) 343 (124)
VO2 max, mL/kg/min, mean (SD) 13.9 (3.9)
LVEF, %, mean (SD) 25 (7)
LVESV, mL, mean (SD) 202 (91)
NYHA class III, n (%) 39 (100)
MLWHFQ, mean (SD) 46 (22)
NT-proBNP, pg/mL, mean (SD) 2932 (3028)
Reproduced with permission from Jessup et al. [35].
CUPID, Calcium Upregulation by Percutaneous Administration of Gene Therapy
in Cardiac Disease; SD, standard deviation; n, number; HF, heart failure; 6MWT,
6-minute walk test; VO2 max, peak oxygen consumption; mL/kg/min,
milliliters/kilogram/minute; LVEF, left ventricular ejection fraction; LVESV,
left ventricular end-systolic volume; NYHA, New York Heart Association;
MLWHFQ, Minnesota Living With Heart Failure Questionnaire; NT-proBNP,
N-terminal prohormone brain natriuretic peptide.
Fig. 2. Summary of the changes in heart failure domains seen after treatment
with adeno-associated virus (AAV)1/sarco(endo)plasmic reticulum Ca2+ATPase
(SERCA2a) or placebo. Patients treated with placebo demonstrated evidence of
worsening over the 12-month follow-up period. In contrast, the clinical course
of patients who received high-dose AAV1/SERCA2a therapy appears to have
stabilized or improved. NT-proBNP, N-terminal pro-B-type natriuretic peptide.
Reproduced with permission from Jessup et al. [35].
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associated with an 88% (p < 0.01) risk reduction at the end of
1 year and an effect of almost equal magnitude at 81% has been
maintained over the 3-year period of follow-up. A trend toward a
reduction in mortality at the end of 3 years was also seen.Fig. 3. Cardiovascular and Terminal Events in Calcium Upregulation by Percutaneous Ad
clinical course for study patients starting from the date of infusion of AAV1/SERCA2a 
represents a patient with anti-AAV1 NAb titer that was <1:2 during screening but 
containing human sarcoplasmic reticulum Ca2+ATPase 2a (SERCA2a) gene; LVAD, left 
neutralizing antibody (NAb) at baseline; WHF, worsening heart failure.
Reproduced with permission from Greenberg et al. [38].One important question regarding the use of SERCA2a gene
transfer therapy in heart failure patients is whether there is
evidence of persistent transgene expression in the myocardium.
The availability of tissue from patients in CUPID who underwent
cardiac transplantation or left ventricular assist device (LVAD)
implantation provided an opportunity to assess whether this was
the case. From the limited number of tissue samples available there
is evidence that patients who were treated with high-dose
SERCA2a gene transfer therapy who had low neutralizing antibody
titers at the time of administration of the viral construct had
evidence of transgene expression in the myocardium with the
longest time from administration to sampling being 31 months
[36]. Ongoing surveillance of the CUPID population should provide
additional needed information about the longevity of transgene
expression in treated patients.
Based on the encouraging results of CUPID, the pivotal CUPID
2 study was undertaken [38]. In CUPID 2, 250 advanced heart
failure patients from sites in the USA and Europe were randomized
to receive either high-dose AAV1/SERCA2a gene transfer therapy
or placebo in a blinded fashion. Entry criteria for CUPID 2 were
similar to those used in CUPID, except that the population was
enriched to include patients at increased risk of events based on
either recent heart failure hospitalization within the past 6 months
or elevated levels of natriuretic peptide measured within 30 days
of randomization. The study is event driven with a primary
endpoint of 186 recurrent heart failure hospitalizations or terminal
(death, cardiac transplantation or LVAD) events with patients
required to be followed for at least 1 year in order to test the
hypothesis that high-dose SERCA2a gene transfer will improveministration of Gene Therapy in Cardiac Disease phase 2. This ﬁgure represents the
or placebo; each line represents a single patient. A star at the beginning of a line
1:2 at baseline. AAV1/SERCA2a, recombinant adeno-associated viral vector (AAV)
ventricular assist device; MI, myocardial infarction; NAb+, positive for anti-AAV1
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primary events has been achieved in this study and the 1-year
follow-up for all patients will be completed early in 2015.
Future directions
Although gene transfer therapy appears to be promising for
treating heart failure, there are many issues that remain. The most
immediate is in regards to the presence of neutralizing antibodies.
AAV-related disease (which is mostly clinically silent or mild in
nature) is common in the population and many people develop
titers of neutralizing antibodies in response to these infections.
The presence of these antibodies, however, appears to adversely
affect the efﬁcacy of treatment and it is currently recommended
that only patients with titers of <1.2 be treated. In CUPID 2, in
which serum samples were collected from over 1500 patients,
60% were excluded based on antibody titers. Although there was
signiﬁcant variability between countries, no speciﬁc patterns could
be detected. Only patient age correlated with qualifying AAV1
neutralizing antibody titers. If these results are representative,
then the presence of such antibody titers will be an important
impediment to AAV-based gene transfer approaches. Studies
aimed at reducing antibody titers either by medical therapy,
plasma exchange, or other approaches will need to be carried out
in order to make this therapy more widely available.
Despite the fact that currently available AAV vectors demon-
strate high avidity for cardiac tissue, uptake in other organs and
tissue throughout the body occurs raising the possibility of off-
target effects of therapy that could be harmful. Thus, continued
development of more cardiac-speciﬁc vectors is needed. Similarly,
developing vectors that can deliver genetic material beyond the
currently limited transgene size would be an important step
forward. Constructs currently being developed for gene transfer
therapy utilize strong promoters (e.g. the cytomegalovirus
promoter is used to drive SERC2a) in order to maximize transgene
expression. While this may be helpful initially, it is less certain
whether continued high-level expression of the therapeutic gene
will be helpful and could, potentially, be harmful. Therefore,
systems in which transgene expression could be regulated
according to prevailing conditions or need and which could be
shut off if shown to be deleterious would be advantageous for
future work in this area. Finally, deﬁning new targets (e.g.
receptors, signaling molecules, structural proteins or enzyme)
that are amenable to modiﬁcation by gene transfer techniques
remains an important future consideration.
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